Fundraising Fox
/Companies
Sign in

AviadoBio

Founded 2019 · 72 employees on LinkedIn · 7 known investors

Find your way into AviadoBio

Sign up to see every warm intro you have to AviadoBio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the AviadoBio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

AviadoBio is a gene therapy company developing adeno-associated viral (AAV) treatments for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). It is a spinout from King's College London research focused on the genetics and molecular biology of these diseases.

BiotechDeep TechDigital HealthHealthtech

Founders & leadership

AviadoBio was founded in 2019 by Chris Shaw, Do Young Lee, and Youn Bok Lee.

CSChris Shaw
Chris ShawCo-Founder & Chief Scientific and Clinical AdvisorChris Shaw is a neurologist and neurogeneticist with over 25 years of clinical and research experience in amyotrophic lateral sclerosis and frontotemporal dementia. He directs the Maurice Wohl Clinical Neurosciences Institute at King's College London and leads research that has identified multiple disease-associated genes; he co-founded AviadoBio to develop AAV-based gene therapy treatments for these neurodegenerative disorders.
DYDo Young Lee
Do Young LeeCo-Founder
YBYoun Bok Lee
Youn Bok LeeCo-FounderCo-Founder at AviadoBio Website
LDLisa Deschamps
Lisa DeschampsChief Executive OfficerLisa Deschamps spent over 25 years at Novartis, including as Senior Vice President and Chief Business Officer of Novartis Gene Therapies, where she oversaw commercialization of gene therapy products including Zolgensma, and has held leadership roles across multiple therapeutic areas and global regions. She holds an MBA in General Management from NYU Stern School of Business and a BBA in Marketing from Iona University.
GFGraeme Fielder
Graeme FielderChief Operating OfficerGraeme Fielder is a biomedical scientist with background in preclinical drug discovery and technology commercialization across biotech, agriculture, and food sectors. As Chief Operating Officer of AviadoBio, he works on developing genetic medicines for neurodegenerative diseases.
ABAlex Bloom
Alex BloomChief Development OfficerChief Development Officer at AviadoBio Website
DCDavid Cooper
David CooperChief Medical OfficerChief Medical Officer at AviadoBio Website
FSFarah Speer
Farah SpeerSVP, Communications & External RelationsFarah Speer holds an MBA from the University of Notre Dame and a BS in mass communication from Boston University. She has held leadership roles in healthcare communications and marketing across pharmaceutical, biotech, and consumer healthcare organizations, with experience in FDA approval messaging, investor relations, and patient advocacy programs.
JIJohn Isaac
John IsaacChief Scientific OfficerChief Scientific Officer at AviadoBio Website

Investors · 7

Dementia Discoverylisted by Dementia DiscoveryLondon

How we know: Dementia Discovery's portfolio page · Not right? Tell us

F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M

How we know: F-Prime Capital's portfolio page · Not right? Tell us

LifeArc Ventureslisted by LifeArc VenturesLondon

How we know: LifeArc Ventures's portfolio page · Not right? Tell us

Monograph Capital Partnerslisted by Monograph Capital PartnersLondon
New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

SV Health InvestorsreportedLondon · $1M – $20M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Founder mafia

5 people who came through AviadoBio went on to found or lead other companies.

Jeff GoaterChairFounded Atavistik BioTim FunnellInvestor DirectorFounded Ascend Advanced TherapiesJoanna WolakBoard MemberFounded EndLyz TherapeuticsGraeme FielderChief Operating OfficerFounded ChiasmaAmber SalzmanBoard MemberFounded Epicrispr Biotechnologies

Frequently asked questions

What does AviadoBio do?
AviadoBio is a gene therapy company developing adeno-associated viral (AAV) treatments for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). It is a spinout from King's College London research focused on the genetics and molecular biology of these diseases.
Who founded AviadoBio?
AviadoBio was founded by Chris Shaw, Do Young Lee, Youn Bok Lee in 2019.
Who are AviadoBio's investors?
AviadoBio's investors include Advent Life Sciences, Dementia Discovery, F-Prime Capital, LifeArc Ventures, Monograph Capital Partners, New Enterprise Associates (NEA), SV Health Investors.